The efficacy of ICI therapy was limited by a paucity of activated CD103+ DC in melanoma lesions [49], and a DC gene signature was strongly associated with improved patient OS in NSCLC patients undergoing atezolizumab therapy [50]. The gene discussed is ITGAE; the disease is melanoma.